Josep M. Llovet

Josep M. Llovet, MD, PhD is Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai, New York, USA. Furthermore, he is ICREA Research Professor at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the University of Barcelona in Spain.

He has published 359 manuscripts (h-index:151, citations:145,040), and have been awarded by Clarivate Analytics as a top 1% cited investigator in all years from 2014 to 2024. His research has been focused on clinical and translational studies in liver cancer for the last 30 years, with the following achievements: a) Leading author/ Principal investigator of RCT leading to standard of care therapies for hepatocellular carcinoma (HCC), such as systemic treatment (sorafenib), chemoembolization and latelly combination of lenvatinib plus pembrolizumab plus TACE, in intermediate HCC.

In addition, he has led proposals of molecular and immune classification of HCC (2008,2017, 2023) and established an imaging criteria for assessment of response to therapies (modified RECIST).

In terms of participation in scientific institutions, he has been Founder, Secretary and President of the International Liver Cancer Association (ILCA); Founder and Director of the Mount Sinai Liver Cancer Program (2005-2023), the first program on liver cancer recognized by NCI in the USA; and c) Principal investigator of research funding with > 110 competitive grants, including coordinator of 2 European Union FP7 and Horizon Europe grants and 2 NIH-RO1.